Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Goupille

Showing results (31-40 of 128) with videos related to

Pageof 13
Sort By:
British Journal of Clinical Pharmacology|August 28, 2019
CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritisAmina Bensalem, Denis Mulleman, Gilles Thibault, et al.
Joint Bone Spine|December 10, 2008
Infliximab for treating axial spondylarthropathy in everyday practiceIsabelle Griffoul, Bruno Giraudeau, Denis Mulleman, et al.
Arthritis Research & Therapy|July 25, 2009
Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohortJacques-Eric Gottenberg, Corinne Miceli-Richard, Béatrice Ducot, et al.
Rheumatology (Oxford, England)|January 19, 2010
Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in FranceAlain Saraux, Laure Gossec, Philippe Goupille, et al.
Joint Bone Spine|November 15, 2025
The changing face of axial spondyloarthritis over the last 25 yearsDaniel Wendling, Philippe Goupille, Renaud Felten, et al.
Arthritis Research & Therapy|June 7, 2011
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative studyDenis Mulleman, Francine Lauféron, Daniel Wendling, et al.
The Journal of Rheumatology|December 3, 2010
Direct cost-modeling of rheumatoid arthritis according to disease activity categories in FranceAriel Beresniak, Laure Gossec, Philippe Goupille, et al.
The Journal of Rheumatology|February 9, 2018
Application of Recommendations Regarding the Use of Subcutaneous Tumor Necrosis Factor Inhibitors in Spondyloarthritis by Rheumatologists in Daily PracticeCéline Pereira-Gillion, Mathilde Marot, Isabelle Griffoul-Espitalier, et al.
Joint Bone Spine|September 18, 2020
Pregnancy rates and outcomes in early axial spondyloarthritis: An analysis of the DESIR cohortMarion Pons, Maxime Dougados, Nathalie Costedoat-Chalumeau, et al.
European Journal of Dermatology : EJD|April 14, 2020
High pre-treatment neutrophil-to-lymphocyte ratio in patients with dermatomyositis/polymyositis predicts an increased risk of cancerIrène Nicoletis, Jeremy Pasco, François Maillot, et al.
Pageof 13

Showing results (31-40 of 128) with videos related to

Sort By:
Pageof 13
British Journal of Clinical Pharmacology|August 28, 2019
CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritisAmina Bensalem, Denis Mulleman, Gilles Thibault, et al.
Joint Bone Spine|December 10, 2008
Infliximab for treating axial spondylarthropathy in everyday practiceIsabelle Griffoul, Bruno Giraudeau, Denis Mulleman, et al.
Arthritis Research & Therapy|July 25, 2009
Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohortJacques-Eric Gottenberg, Corinne Miceli-Richard, Béatrice Ducot, et al.
Rheumatology (Oxford, England)|January 19, 2010
Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in FranceAlain Saraux, Laure Gossec, Philippe Goupille, et al.
Joint Bone Spine|November 15, 2025
The changing face of axial spondyloarthritis over the last 25 yearsDaniel Wendling, Philippe Goupille, Renaud Felten, et al.
Arthritis Research & Therapy|June 7, 2011
Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative studyDenis Mulleman, Francine Lauféron, Daniel Wendling, et al.
The Journal of Rheumatology|December 3, 2010
Direct cost-modeling of rheumatoid arthritis according to disease activity categories in FranceAriel Beresniak, Laure Gossec, Philippe Goupille, et al.
The Journal of Rheumatology|February 9, 2018
Application of Recommendations Regarding the Use of Subcutaneous Tumor Necrosis Factor Inhibitors in Spondyloarthritis by Rheumatologists in Daily PracticeCéline Pereira-Gillion, Mathilde Marot, Isabelle Griffoul-Espitalier, et al.
Joint Bone Spine|September 18, 2020
Pregnancy rates and outcomes in early axial spondyloarthritis: An analysis of the DESIR cohortMarion Pons, Maxime Dougados, Nathalie Costedoat-Chalumeau, et al.
European Journal of Dermatology : EJD|April 14, 2020
High pre-treatment neutrophil-to-lymphocyte ratio in patients with dermatomyositis/polymyositis predicts an increased risk of cancerIrène Nicoletis, Jeremy Pasco, François Maillot, et al.
Pageof 13